Insulin secretion deficits in a Prader-Willi syndrome -cell model are associated with a concerted downregulation of multiple endoplasmic reticulum chaperones
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
Visit us at Centrum Pharmacy to experience the difference of true patient-centered care
Researchers measured, as primary outcomes, psychiatric hospitalisation, sick leave from work for more than 14 days for psychiatric reasons, hospitalisation due to self-harm, or taking ones own life
Noom and WeightWatchers together account for roughly 60% of global weight loss app revenue
UK consumers should be aware that supplement companies can make structure-function claims without proving they work, unlike prescription medications, which require extensive clinical trials
